COVID-19 infection and vaccination rarely impact HLA antibody profile in waitlisted renal transplant candidates- a multicenter cohort.


Journal

Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 17 11 2022
revised: 18 02 2023
accepted: 20 02 2023
medline: 3 4 2023
pubmed: 4 3 2023
entrez: 3 3 2023
Statut: ppublish

Résumé

Although rare, infection and vaccination can result in antibodies to human leukocyte antigens (HLA). We analyzed the effect of SARS-CoV-2 infection or vaccination on HLA antibodies in waitlisted renal transplant candidates. Specificities were collected and adjudicated if the calculated panel reactive antibodies (cPRA) changed after exposure. Of 409 patients, 285 (69.7 %) had an initial cPRA of 0 %, and 56 (13.7 %) had an initial cPRA > 80 %. The cPRA changed in 26 patients (6.4 %), 16 (3.9 %) increased, and 10 (2.4 %) decreased. Based on cPRA adjudication, cPRA differences generally resulted from a small number of specificities with subtle fluctuations around the borderline of the participating centers' cutoff for unacceptable antigen listing. All five COVID recovered patients with an increased cPRA were female (p = 0.02). In summary, exposure to this virus or vaccine does not increase HLA antibody specificities and their MFI in approximately 99 % of cases and 97 % of sensitized patients. These results have implications for virtual crossmatching at the time of organ offer after SARS-CoV-2 infection or vaccination, and these events of unclear clinical significance should not influence vaccination programs.

Identifiants

pubmed: 36868898
pii: S0198-8859(23)00041-1
doi: 10.1016/j.humimm.2023.02.005
pmc: PMC9946887
pii:
doi:

Substances chimiques

Antibodies 0
HLA Antigens 0
Isoantibodies 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-285

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Garrett R Roll (GR)

Department of Surgery, University of California San Francisco, San Francisco, CA, United States.

Robert A Bray (RA)

Histocompatibility and Molecular Immunogenetics Laboratory, Emory University, Atlanta, GA, United States.

Matthew Cooper (M)

Medstar-Georgetown Transplant Institute, Washington, DC, United States.

Todd N Eagar (TN)

Immunogenetics and Transplantation Laboratory Houston Methodist, Houston, TX, United States.

Howard M Gebel (HM)

Histocompatibility and Molecular Immunogenetics Laboratory, Emory University, Atlanta, GA, United States.

Gayle M Vranic (GM)

Medstar-Georgetown Transplant Institute, Washington, DC, United States.

Kelley M K Hitchman (KMK)

Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, San Antonio, San Antonio, TX, United States.

Julie Houp (J)

Department of Laboratory Medicine, University of Alabama Medical Center, Birmingham, AL, United Kingdom.

Malek Kamoun (M)

Department of Pathology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.

John Killian (J)

Department of Surgery, University of Alabama Medical Center, Birmingham, AL, United Kingdom.

Jim Kim (J)

Department of Surgery, University of Southern California, Los Angeles, CA, United States.

Vineeta Kumar (V)

Department of Medicine, Division of Nephrology, University of Alabama, Birmingham, AL, United Kingdom.

Matthew Levine (M)

Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.

Brendan P Lovasik (BP)

Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States.

Tyler Lunow-Luke (T)

Department of Surgery, University of California San Francisco, San Francisco, CA, United States.

Ronald F Parsons (RF)

Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States.

Vikram Pattanayak (V)

Department of Pathology, Massachusetts General Hospital, Boston MA, United States.

Daniel Ranch (D)

Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.

Anushi Shah (A)

Department of Surgery, Massachusetts General Hospital, Boston, MA, United States.

Peter G Stock (PG)

Department of Surgery, University of California San Francisco, San Francisco, CA, United States.

Olga A Timofeeva (OA)

Department of Pathology, MedStar Georgetown University Hospital, Washington, DC, United States.

Jennifer Trofe-Clark (J)

Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.

Chelsey Wongjirad (C)

Department of Surgery, University of Southern California, Los Angeles, CA, United States.

Heidi Yeh (H)

Department of Surgery, Massachusetts General Hospital, Boston, MA, United States.

Stephanie Yi (S)

Department of Surgery, Houston Methodist, Houston, TX, United States.

Raja Rajalingam (R)

Immunogenetics and Transplantation Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, United States. Electronic address: Rajalingam.Raja@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH